(Nano) platforms in bladder cancer therapy: Challenges and opportunities

M Ashrafizadeh, A Zarrabi… - Bioengineering & …, 2023 - Wiley Online Library
Urological cancers are among the most common malignancies around the world. In
particular, bladder cancer severely threatens human health due to its aggressive and …

Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials

JJ Leow, W Martin-Doyle, PS Rajagopal, CG Patel… - European urology, 2014 - Elsevier
Context The role of adjuvant chemotherapy remains poorly defined for the management of
muscle-invasive bladder cancer (MIBC). The last meta-analysis evaluating adjuvant …

Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

AV Kurtova, J Xiao, Q Mo, S Pazhanisamy, R Krasnow… - Nature, 2015 - nature.com
Cytotoxic chemotherapy is effective in debulking tumour masses initially; however, in some
patients tumours become progressively unresponsive after multiple treatment cycles …

Bladder cancer treatment response assessment in CT using radiomics with deep-learning

KH Cha, L Hadjiiski, HP Chan, AZ Weizer, A Alva… - Scientific reports, 2017 - nature.com
Cross-sectional X-ray imaging has become the standard for staging most solid organ
malignancies. However, for some malignancies such as urinary bladder cancer, the ability to …

Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature

LA Kluth, PC Black, BH Bochner, J Catto, SP Lerner… - European urology, 2015 - Elsevier
Context This review focuses on risk assessment and prediction tools for bladder cancer
(BCa). Objective To review the current knowledge on risk assessment and prediction tools to …

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

JJ Meeks, H Al-Ahmadie, BM Faltas… - Nature Reviews …, 2020 - nature.com
Histological and molecular analyses of urothelial carcinoma often reveal intratumoural and
intertumoural heterogeneity at the genomic, transcriptional and cellular levels. Despite the …

[HTML][HTML] Role of immunotherapy in bladder cancer

LP Rhea, S Mendez-Marti, D Kim… - Cancer Treatment and …, 2021 - Elsevier
The role of immunotherapy in bladder urothelial cancers is rapidly expanding. Since the
initial second-line therapy approval for patients who fail prior platinum-based chemotherapy …

Aberrant expression of microRNAs in bladder cancer

H Yoshino, N Seki, T Itesako, T Chiyomaru… - Nature Reviews …, 2013 - nature.com
MicroRNAs (miRNAs), a class of small noncoding RNAs, regulate protein-coding gene
expression by repressing translation or cleaving RNA transcripts in a sequence-specific …

Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review

R Azevedo, JA Ferreira, A Peixoto, M Neves… - Journal of Controlled …, 2015 - Elsevier
Bladder cancer is the most common malignancy of the urinary tract, presents the highest
recurrence rate among solid tumors and is the second leading cause of death in …

Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer

K Miyamoto, N Seki, R Matsushita, M Yonemori… - British journal of …, 2016 - nature.com
Background: Previous studies have revealed that miR-26a-5p and miR-26b-5p act as
tumour suppressors in various types of cancer tissues. Here, we aimed to investigate the …